fda compounding semaglutide warning letters news warnings against compounded GLP-1s raise the stakes for telehealths selling branded drugs FDA Warning Letter Breakdown: Sterility

Patients receiving semaglutide (0.5 or 1.0 mg) for 104 weeks demonstrated a significantly higher risk of diabetic retinopathy complications, including vitreous hemorrhage, blindness, or required procedural treatment compared to those receiving placebo (HR, 1.76

Studies show that stopping semaglutide typically leads to weight regain

Efecto del liraglutide en el control del peso en personas no diabticas con sobrepeso u obesidad (estudio SCALE)

It's worth noting that in the UK, Ozempic is licensed specifically for the treatment of type 2 diabetes, while Wegovy (also semaglutide, but at different doses) is licensed for weight management

GLP-1 primarily reduces appetite and slows gastric emptying, GIP enhances fat metabolism and insulin sensitivity, and glucagon increases energy expenditure and fat oxidation

May 2023